- Home
- CRVS vs NCV Comparison
CRVS vs NCV Comparison
Compare CRVS & NCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- NCV
- Stock Information
- Founded
- CRVS 2014
- NCV 2003
- Country
- CRVS United States
- NCV United States
- Employees
- CRVS N/A
- NCV N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- NCV Finance Companies
- Sector
- CRVS Health Care
- NCV Finance
- Exchange
- CRVS Nasdaq
- NCV Nasdaq
- Market Cap
- CRVS 305.4M
- NCV 326.0M
- IPO Year
- CRVS 2016
- NCV N/A
- Fundamental
- Price
- CRVS $5.75
- NCV $14.75
- Analyst Decision
- CRVS Strong Buy
- NCV
- Analyst Count
- CRVS 4
- NCV 0
- Target Price
- CRVS $15.00
- NCV N/A
- AVG Volume (30 Days)
- CRVS 518.7K
- NCV 405.1K
- Earning Date
- CRVS 08-07-2025
- NCV 01-01-0001
- Dividend Yield
- CRVS N/A
- NCV 12.48%
- EPS Growth
- CRVS N/A
- NCV N/A
- EPS
- CRVS N/A
- NCV N/A
- Revenue
- CRVS N/A
- NCV N/A
- Revenue This Year
- CRVS N/A
- NCV N/A
- Revenue Next Year
- CRVS N/A
- NCV N/A
- P/E Ratio
- CRVS N/A
- NCV N/A
- Revenue Growth
- CRVS N/A
- NCV N/A
- 52 Week Low
- CRVS $2.54
- NCV $2.84
- 52 Week High
- CRVS $10.00
- NCV $3.59
- Technical
- Relative Strength Index (RSI)
- CRVS 65.10
- NCV 66.05
- Support Level
- CRVS $5.28
- NCV $14.27
- Resistance Level
- CRVS $5.64
- NCV $14.78
- Average True Range (ATR)
- CRVS 0.30
- NCV 0.14
- MACD
- CRVS 0.03
- NCV 0.01
- Stochastic Oscillator
- CRVS 77.70
- NCV 90.57
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.